Since the transcriptional analysis revealed that the second tumor cluster (BRAF-GG) carries an increased risk for tumor recurrence (42%) we aimed at validating these results by investigating the BRAF status in patients with recurrent gangliogliomas (and without transcriptional data) from the local database. The gene discussed is BRAF; the disease is ganglioglioma.